Summary

Asia Pacific 3D Bioprinting in Medical Market is valued approximately USD 300 million in 2023 and is anticipated to grow with a healthy growth rate of more than 16.65% over the forecast period 2024-2032. 3D bioprinting in the medical field representing a revolutionary approach to tissue engineering and regenerative medicine. It involves the precise layer-by-layer deposition of biomaterials, cells, and growth factors to create three-dimensional structures that mimic the complex architecture and functionality of native tissues and organs. This cutting-edge technology holds immense promise for a wide range of applications, including organ transplantation, drug screening, disease modeling, and personalized medicine. Asia Pacific 3D printing in medical market is witnessing rapid technological advancement in 3D bioprinting technology, driven by research institutions, biotechnology companies, and government initiatives. Innovations in printing techniques, biomaterials, and bioreactor systems are enhancing the precision, speed, and scalability of bioprinting processes.

Governments across different countries in Asia Pacific region are increasingly investing in research and development initiatives related to 3D bioprinting and regenerative medicine. Government support, grants, subsidies and tax incentives aim to promote innovation, stimulate economic growth, and address healthcare challenges through the advancement of bioprinting technologies. Furthermore, Asia Pacific 3D Bioprinting in Medical Market is driven by growing healthcare expenditure and rising development of regenerative medicine. However, high development costs and limited reimbursement policies is expected to stifle market growth between 2022 and 2032.

The key countries considered for the Asia Pacific 3D Bioprinting in Medical market study includes China, India, Japan, South Korea, Australia and Rest of Asia Pacific. In 2023, South Korea has the largest regional share in the regional market. South Korea boasts a robust infrastructure for research and development, supported by world-class universities, research institutions and government initiatives. These institutions foster innovation and collaboration, driving advancements in 3D bioprinting technology and applications. Additionally, South Korea has a strong focus on healthcare and biotechnology, with significant investment in regenerative medicine and personalized healthcare solutions. The market in China, on the other hand, is expected to grow at the fastest rate over the forecast period.

Major market player included in this report are:
Rokit Healthcare Inc
Regenovo Biotechnology Co, Ltd
Aspect Biosystems
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Products and Solution
Bioprinters
Consumables and accessories
Software and services

By Technology
Extrusion based bioprinting
Inkjet based bioprinting
Laser assisted bioprinting
Others

By Application
Tissue engineering and regenerative medicine
Drug discovery and development
Others

By End User
Biotechnology and pharmaceutical companies
Academic and research institutes
Others

By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Asia Pacific 3D Bioprinting in Medical Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Asia Pacific 3D Bioprinting in Medical Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Products and Solutions
2.3.2. By Technology
2.3.3. By Application
2.3.4. By End User
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Asia Pacific 3D Bioprinting in Medical Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Asia Pacific 3D Bioprinting in Medical Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Asia Pacific 3D Bioprinting in Medical Market Size & Forecasts by Products and Solutions 2022-2032
5.1. Bioprinters
5.2. Consumables and accessories
5.3. Software and services
Chapter 6. Asia Pacific 3D Bioprinting in Medical Market Size & Forecasts by Technology 2022-2032
6.1. Extrusion based bioprinting
6.2. Inkjet based bioprinting
6.3. Laser assisted bioprinting
6.4. Others
Chapter 7. Asia Pacific 3D Bioprinting in Medical Market Size & Forecasts by Application 2022-2032
7.1. Tissue engineering and regenerative medicine
7.2. Drug discovery and development
7.3. Others
Chapter 8. Asia Pacific 3D Bioprinting in Medical Market Size & Forecasts by End User 2022-2032
8.1. Biotechnology and pharmaceutical companies
8.2. Academic and research institutes
8.3. Others
Chapter 9. Asia Pacific 3D Bioprinting in Medical Market Size & Forecasts by Country 2022-2032
9.1. China 3D Bioprinting in Medical Market
9.1.1.1. Products and Solution breakdown size & forecasts, 2022-2032
9.1.1.2. Technology breakdown size & forecasts, 2022-2032
9.1.1.3. Application breakdown size & forecasts, 2022-2032
9.1.1.4. End User breakdown size & forecasts, 2022-2032
9.2. India 3D Bioprinting in Medical Market
9.3. Japan 3D Bioprinting in Medical Market
9.4. Australia 3D Bioprinting in Medical Market
9.5. South Korea 3D Bioprinting in Medical Market
9.6. Rest of Asia Pacific 3D Bioprinting in Medical Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Company 1
10.1.2. Company 2
10.1.3. Company 3
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Rokit Healthcare Inc
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Regenovo Biotechnology Co., Ltd
10.3.3. Aspect Biosystems Ltd
10.3.4. Company 4
10.3.5. Company 5
10.3.6. Company 6
10.3.7. Company 7
10.3.8. Company 8
10.3.9. Company 9
10.3.10. Company 10
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes